{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:21:39Z","timestamp":1783430499746,"version":"3.54.6"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsches Diabetes-Zentrum (DDZ)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aims<\/jats:title>\n                <jats:p>Previous observational studies on glucose-lowering drugs and risk of stroke in type 2 diabetes yielded conflicting results. The aim was to examine the association of glucose-lowering drugs with incident stroke and transient ischaemic attacks (TIA) in newly diagnosed type 2 diabetes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a retrospective cohort analysis of the disease analyzer, which comprises a representative panel of 1248 general and internal medicine practices throughout Germany (01\/2000\u201312\/2019: 9.8 million patients). Incident non-fatal stroke\/TIA was defined based on ICD-10 codes (I63, I64; G45) in newly diagnosed type 2 diabetes. Cox regression models were fitted to obtain hazard ratios (HR; 95%CI) for stroke\/TIA adjusting for potential confounders (age, sex, health insurance, coronary heart disease, myocardial infarction, heart failure, polyneuropathy, blood pressure, eGFR) and anthropometric and metabolic intermediators (BMI, HbA1c, HDL- and LDL-cholesterol, triglycerides, lipid-lowering drugs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Result<\/jats:title>\n                <jats:p>312,368 persons with newly diagnosed type 2 diabetes without previous stroke\/TIA (mean age: 64\u00a0years; 52% males) were included. There were 16,701 events of non-fatal stroke\/TIA corresponding to an incidence rate of 9.3 (95%CI 9.1\u20139.4) per 1000 person-years. Using Cox regression, adjusted HR for stroke\/TIA (per 1\u00a0year of treatment) of 0.59 (0.54\u20130.64) for SGLT2 inhibitors and of 0.79 (0.74\u20130.85) for GLP-1 receptor agonists were estimated. DPP-4 inhibitors (0.84; 0.82\u20130.86), metformin (0.90; 0.89\u20130.91), insulin (0.92; 0.91\u20130.93) and sulfonylureas (0.98; 0.96\u20130.99) also showed moderately reduced HR for stroke\/TIA. Sex-specific regression analyses yielded similar results (HR).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Treatment with SGLT2 inhibitors or GLP-1 receptor agonists might reduce non-fatal stroke\/TIA in persons with newly diagnosed type 2 diabetes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00592-022-01943-7","type":"journal-article","created":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T19:29:05Z","timestamp":1659814145000},"page":"1443-1451","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Association of glucose-lowering drugs with incident stroke and transient ischaemic attacks in primary care patients with type 2 diabetes: disease analyzer database"],"prefix":"10.1007","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7804-1740","authenticated-orcid":false,"given":"Wolfgang","family":"Rathmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2124-7227","authenticated-orcid":false,"given":"Karel","family":"Kostev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,6]]},"reference":[{"issue":"5","key":"1943_CR1","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/eurheartj\/ehq472","volume":"32","author":"M Endres","year":"2011","unstructured":"Endres M, Heuschmann PU, Laufs U, Hakim AM (2011) Primary prevention of stroke: blood pressure, lipids, and heart failure. Eur Heart J 32(5):545\u2013552. https:\/\/doi.org\/10.1093\/eurheartj\/ehq472","journal-title":"Eur Heart J"},{"issue":"4","key":"1943_CR2","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.amjms.2016.01.011","volume":"351","author":"R Chen","year":"2016","unstructured":"Chen R, Ovbiagele B, Feng W (2016) Diabetes and stroke: epidemiology, pathophysiology, pharmaceuticals and outcomes. Am J Med Sci 351(4):380\u2013386. https:\/\/doi.org\/10.1016\/j.amjms.2016.01.011","journal-title":"Am J Med Sci"},{"issue":"5","key":"1943_CR3","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1212\/WNL.0000000000004173","volume":"89","author":"SC Larsson","year":"2017","unstructured":"Larsson SC, Scott RA, Traylor M et al (2017) Type 2 diabetes, glucose, insulin, BMI, and ischemic stroke subtypes: Mendelian randomization study. Neurology 89(5):454\u2013460. https:\/\/doi.org\/10.1212\/WNL.0000000000004173","journal-title":"Neurology"},{"key":"1943_CR4","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S et al (2022) IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 183:109119. https:\/\/doi.org\/10.1016\/j.diabres.2021.109119","journal-title":"Diabetes Res Clin Pract"},{"issue":"7","key":"1943_CR5","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1007\/s00125-021-05436-0","volume":"64","author":"M Benn","year":"2021","unstructured":"Benn M, Emanuelsson F, Tybj\u00e6rg-Hansen A, Nordestgaard BG (2021) Impact of high glucose levels and glucose lowering on risk of ischaemic stroke: a Mendelian randomisation study and meta-analysis. Diabetologia 64(7):1492\u20131503. https:\/\/doi.org\/10.1007\/s00125-021-05436-0","journal-title":"Diabetologia"},{"issue":"1","key":"1943_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/0271678X20952011","volume":"41","author":"MP Maskery","year":"2021","unstructured":"Maskery MP, Holscher C, Jones SP et al (2021) Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review. J Cereb Blood Flow Metab 41(1):14\u201330. https:\/\/doi.org\/10.1177\/0271678X20952011","journal-title":"J Cereb Blood Flow Metab"},{"issue":"2","key":"1943_CR7","doi-asserted-by":"publisher","first-page":"e0244689","DOI":"10.1371\/journal.pone.0244689","volume":"16","author":"CX Li","year":"2021","unstructured":"Li CX, Liang S, Gao L, Liu H (2021) Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: a real-world systematic review and meta-analysis. PLoS ONE 16(2):e0244689. https:\/\/doi.org\/10.1371\/journal.pone.0244689","journal-title":"PLoS ONE"},{"issue":"10","key":"1943_CR8","doi-asserted-by":"publisher","first-page":"459","DOI":"10.5414\/CP203320","volume":"56","author":"W Rathmann","year":"2018","unstructured":"Rathmann W, Bongaerts B, Carius HJ, Kruppert S, Kostev K (2018) Basic characteristics and representativeness of the German Disease Analyzer database. Int J Clin Pharmacol Ther 56(10):459\u2013466. https:\/\/doi.org\/10.5414\/CP203320","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"10","key":"1943_CR9","doi-asserted-by":"publisher","first-page":"617","DOI":"10.5414\/cpp47617","volume":"47","author":"H Becher","year":"2009","unstructured":"Becher H, Kostev K, Schr\u00f6der-Bernhardi D (2009) Validity and representativeness of the \u201cdisease analyzer\u201d patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther 47(10):617\u2013626. https:\/\/doi.org\/10.5414\/cpp47617","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1943_CR10","doi-asserted-by":"publisher","first-page":"m4573","DOI":"10.1136\/bmj.m4573","volume":"372","author":"SC Palmer","year":"2021","unstructured":"Palmer SC, Tendal B, Mustafa RA et al (2021) Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 372:m4573. https:\/\/doi.org\/10.1136\/bmj.m4573","journal-title":"BMJ"},{"issue":"8","key":"1943_CR11","doi-asserted-by":"publisher","first-page":"e186125","DOI":"10.1001\/jamanetworkopen.2018.6125","volume":"1","author":"MJ O'Brien","year":"2018","unstructured":"O\u2019Brien MJ, Karam SL, Wallia A et al (2018) Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes. JAMA Netw Open 1(8):e186125. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.6125","journal-title":"JAMA Netw Open"},{"key":"1943_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12933-015-0178-3","volume":"14","author":"SK Paul","year":"2015","unstructured":"Paul SK, Klein K, Maggs D, Best JH (2015) The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study. Cardiovasc Diabetol 14:10. https:\/\/doi.org\/10.1186\/s12933-015-0178-3","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"1943_CR13","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1111\/dom.12969","volume":"19","author":"RS Zimmerman","year":"2017","unstructured":"Zimmerman RS, Hobbs TM, Wells BJ et al (2017) Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system. Diabetes Obes Metab 19(11):1555\u20131561. https:\/\/doi.org\/10.1111\/dom.12969","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1943_CR14","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S2213-8587(18)30320-6","volume":"7","author":"H Svanstr\u00f6m","year":"2019","unstructured":"Svanstr\u00f6m H, Ueda P, Melbye M et al (2019) Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden. Lancet Diabetes Endocrinol 7(2):106\u2013114. https:\/\/doi.org\/10.1016\/S2213-8587(18)30320-6","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1943_CR15","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-1993","author":"YS Yang","year":"2022","unstructured":"Yang YS, Chen HH, Huang CN, Hsu CY, Hu KC, Kao CH (2022) GLP-1RAs for ischemic stroke prevention in patients with type 2 diabetes without established atherosclerotic cardiovascular disease. Diabetes Care. https:\/\/doi.org\/10.2337\/dc21-1993","journal-title":"Diabetes Care"},{"issue":"2","key":"1943_CR16","doi-asserted-by":"publisher","first-page":"e0148827","DOI":"10.1371\/journal.pone.0148827","volume":"11","author":"H Zhang","year":"2016","unstructured":"Zhang H, Liu Y, Guan S et al (2016) An orally active allosteric GLP-1 receptor agonist is neuroprotective in cellular and rodent models of stroke. PLoS ONE 11(2):e0148827. https:\/\/doi.org\/10.1371\/journal.pone.0148827","journal-title":"PLoS ONE"},{"issue":"1","key":"1943_CR17","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12974-019-1638-6","volume":"16","author":"Y Shan","year":"2019","unstructured":"Shan Y, Tan S, Lin Y et al (2019) The glucagon-like peptide-1 receptor agonist reduces inflammation and blood-brain barrier breakdown in an astrocyte-dependent manner in experimental stroke. J Neuroinflamm 16(1):242. https:\/\/doi.org\/10.1186\/s12974-019-1638-6","journal-title":"J Neuroinflamm"},{"issue":"6","key":"1943_CR18","doi-asserted-by":"publisher","first-page":"e02190","DOI":"10.1002\/brb3.2190","volume":"11","author":"Y Li","year":"2021","unstructured":"Li Y, Gong M (2021) Analysis of the neuroprotective effect of GLP-1 receptor agonist peptide on cerebral ischemia-reperfusion injury by quantitative proteomics mass spectrometry. Brain Behav 11(6):e02190. https:\/\/doi.org\/10.1002\/brb3.2190","journal-title":"Brain Behav"},{"issue":"1","key":"1943_CR19","doi-asserted-by":"publisher","first-page":"15364","DOI":"10.1038\/s41598-021-94945-4","volume":"11","author":"WH Tsai","year":"2021","unstructured":"Tsai WH, Chuang SM, Liu SC et al (2021) Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis. Sci Rep 11(1):15364. https:\/\/doi.org\/10.1038\/s41598-021-94945-4","journal-title":"Sci Rep"},{"key":"1943_CR20","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1253\/circj.CJ-17-0040","volume":"81","author":"G Kimura","year":"2017","unstructured":"Kimura G (2017) Sodium-glucose cotransporter 2 (SGLT2) inhibitors and stroke. Circ J 81:898. https:\/\/doi.org\/10.1253\/circj.CJ-17-0040","journal-title":"Circ J"},{"issue":"4","key":"1943_CR21","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jash.2014.01.007","volume":"8","author":"WL Baker","year":"2014","unstructured":"Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB (2014) Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 8(4):262\u2013275. https:\/\/doi.org\/10.1016\/j.jash.2014.01.007","journal-title":"J Am Soc Hypertens"},{"issue":"10017","key":"1943_CR22","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0140-6736(15)00805-3","volume":"387","author":"X Xie","year":"2016","unstructured":"Xie X, Atkins E, Lv J et al (2016) Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387(10017):435\u2013443. https:\/\/doi.org\/10.1016\/S0140-6736(15)00805-3","journal-title":"Lancet"},{"issue":"2","key":"1943_CR23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","volume":"3","author":"AD Shah","year":"2015","unstructured":"Shah AD, Langenberg C, Rapsomaniki E et al (2015) Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1\u00b79 million people. Lancet Diabetes Endocrinol 3(2):105\u2013113. https:\/\/doi.org\/10.1016\/S2213-8587(14)70219-0","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"52","key":"1943_CR24","doi-asserted-by":"publisher","first-page":"e2282","DOI":"10.1097\/MD.0000000000002282","volume":"94","author":"CC Liao","year":"2015","unstructured":"Liao CC, Shih CC, Yeh CC et al (2015) Impact of diabetes on stroke risk and outcomes: two nationwide retrospective cohort studies. Medicine (Baltimore) 94(52):e2282. https:\/\/doi.org\/10.1097\/MD.0000000000002282","journal-title":"Medicine (Baltimore)"},{"issue":"23","key":"1943_CR25","doi-asserted-by":"publisher","first-page":"7213","DOI":"10.3390\/molecules26237213","volume":"26","author":"A Pawlos","year":"2021","unstructured":"Pawlos A, Broncel M, Wo\u017aniak E, Gorzelak-Pabi\u015b P (2021) Neuroprotective effect of SGLT2 inhibitors. Molecules 26(23):7213. https:\/\/doi.org\/10.3390\/molecules26237213","journal-title":"Molecules"},{"issue":"2","key":"1943_CR26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Pitt B et al (2021) Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 384(2):129\u2013139. https:\/\/doi.org\/10.1056\/NEJMoa2030186","journal-title":"N Engl J Med"},{"issue":"30","key":"1943_CR27","doi-asserted-by":"publisher","first-page":"e26431","DOI":"10.1097\/MD.0000000000026431","volume":"100","author":"XY Duan","year":"2021","unstructured":"Duan XY, Liu SY, Yin DG (2021) Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: a network meta-analysis based on cardiovascular or renal outcome trials. Medicine (Baltimore) 100(30):e26431. https:\/\/doi.org\/10.1097\/MD.0000000000026431","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"1943_CR28","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10557-021-07291-y","volume":"36","author":"B Pitt","year":"2022","unstructured":"Pitt B, Steg G, Leiter LA, Bhatt DL (2022) The role of combined SGLT1\/SGLT2 inhibition in reducing the incidence of stroke and myocardial infarction in patients with type 2 diabetes mellitus. Cardiovasc Drugs Ther 36(3):561\u2013567. https:\/\/doi.org\/10.1007\/s10557-021-07291-y","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"1943_CR29","doi-asserted-by":"publisher","first-page":"e1001992","DOI":"10.1371\/journal.pmed.1001992","volume":"13","author":"D Varvaki Rados","year":"2016","unstructured":"Varvaki Rados D, Catani Pinto L, Reck Remonti L, Bauermann Leit\u00e3o C, Gross JL (2016) The association between sulfonylurea use and all-cause and cardiovascular mortality: a meta-analysis with trial sequential analysis of randomized clinical trials. PLoS Med 13(4):e1001992. https:\/\/doi.org\/10.1371\/journal.pmed.1001992","journal-title":"PLoS Med"},{"issue":"10","key":"1943_CR30","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/dom.12116","volume":"15","author":"M Monami","year":"2013","unstructured":"Monami M, Genovese S, Mannucci E (2013) Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 15(10):938\u2013953. https:\/\/doi.org\/10.1111\/dom.12116","journal-title":"Diabetes Obes Metab"},{"key":"1943_CR31","doi-asserted-by":"publisher","first-page":"107836","DOI":"10.1016\/j.diabres.2019.107836","volume":"157","author":"DR Webb","year":"2019","unstructured":"Webb DR, Davies MJ, Jarvis J, Seidu S, Khunti K (2019) The right place for Sulphonylureas today. Diabetes Res Clin Pract 157:107836. https:\/\/doi.org\/10.1016\/j.diabres.2019.107836","journal-title":"Diabetes Res Clin Pract"},{"issue":"19","key":"1943_CR32","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1136\/heartjnl-2015-309164","volume":"102","author":"U Anyanwagu","year":"2016","unstructured":"Anyanwagu U, Mamza J, Mehta R, Donnelly R, Idris I (2016) Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes. Heart 102(19):1581\u20131587. https:\/\/doi.org\/10.1136\/heartjnl-2015-309164","journal-title":"Heart"},{"issue":"2","key":"1943_CR33","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/dom.13525","volume":"21","author":"S Kuo","year":"2019","unstructured":"Kuo S, Yang CT, Wu JS, Ou HT (2019) Effects on clinical outcomes of intensifying triple oral antidiabetic drug (OAD) therapy by initiating insulin versus enhancing OAD therapy in patients with type 2 diabetes: A nationwide population-based, propensity-score-matched cohort study. Diabetes Obes Metab 21(2):312\u2013320. https:\/\/doi.org\/10.1111\/dom.13525","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1943_CR34","doi-asserted-by":"publisher","first-page":"23826","DOI":"10.1038\/s41598-021-02670-9","volume":"11","author":"JC Bazo-Alvarez","year":"2021","unstructured":"Bazo-Alvarez JC, Pal K, Pham TM, Nazareth I, Petersen I, Sharma M (2021) Cardiovascular outcomes of type 2 diabetic patients treated with DPP-4 inhibitors versus sulphonylureas as add-on to metformin in clinical practice. Sci Rep 11(1):23826. https:\/\/doi.org\/10.1038\/s41598-021-02670-9","journal-title":"Sci Rep"},{"issue":"12","key":"1943_CR35","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1007\/s00125-006-0493-z","volume":"49","author":"HE Mulnier","year":"2006","unstructured":"Mulnier HE, Seaman HE, Raleigh VS et al (2006) Risk of stroke in people with type 2 diabetes in the UK: a study using the general practice research database. Diabetologia 49(12):2859\u20132865. https:\/\/doi.org\/10.1007\/s00125-006-0493-z","journal-title":"Diabetologia"}],"updated-by":[{"DOI":"10.1007\/s00592-022-01962-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000}}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-022-01943-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-022-01943-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-022-01943-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T15:10:26Z","timestamp":1664377826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-022-01943-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,6]]},"references-count":35,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["1943"],"URL":"https:\/\/doi.org\/10.1007\/s00592-022-01943-7","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00592-022-01962-4","asserted-by":"object"}]},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,6]]},"assertion":[{"value":"17 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00592-022-01962-4","URL":"https:\/\/doi.org\/10.1007\/s00592-022-01962-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"WR reports the receipt of consulting fees for attending educational sessions or advisory boards run by AstraZeneca, Boehringer Ingelheim, NovoNordisk and IQVIA and institutional research grants from NovoNordisk outside of the topic of the current study. KK is an employee of IQVIA, a healthcare data science company in Germany.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical review and approval were not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"This manuscript has not been published or presented elsewhere in part or in entirety, and is not under consideration by another journal.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}